Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 10/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512224 | 0.90 | BRAF (0.51) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL3510114 | 0.85 | BRAF (0.54) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL3510563 | 0.84 | BRAF (0.58) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL2452684 | 0.84 | BRAF (0.67) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL1259624 | 0.83 | BRAF (0.36) | BRAFMAPK14ABL1 | |
| SCHEMBL3512217 | 0.82 | BRAF (0.46) | BRAFKDRNPC1RAB9A | |
| SCHEMBL14949669 | 0.82 | BRAF (0.55) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL1258338 | 0.82 | BRAF (0.56) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL12892687 | 0.81 | BRAF (0.71) | BRAFKDRPDGFRBKITFLT1 | |
| SCHEMBL1259255 | 0.79 | BRAF (0.45) | BRAFKDRPDGFRBKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | BRAF 84/4885KDR 966/4885PDGFRB 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.